Canada: China’s New Foreign Investment Legislation Encourages Participation In Biotech Industry

Last Updated: March 21 2007
Article by Peng Fu and Cheryl V. Reicin

Originally published in The Lawyers Weekly, March 2, 2007.

China offers enormous, but largely unrealized, opportunities for North American biotechnology and pharmaceutical firms. Those looking to either gain a market foothold or acquire complementary capabilities, products and platform technologies may benefit from a low cost base for research and development, liberal policies toward discovery and clinical research, a large pool of qualified researchers and technologists, and ever-increasing government funding and incentives.

Until recently, the vast majority of foreign direct investments in the Chinese biotechnology sector have come from large multinational pharmaceutical companies, and many of those investments have taken the form of joint ventures. However, China’s gradual relaxation of its historical opposition to foreign ownership of domestic companies has prompted firms to look beyond joint ventures as the primary vehicle for participating in the Chinese biotechnology industry.

Mergers and acquisitions (M&As) are becoming the preferred method of participation, because they enable greater control over quality, intellectual property and other strategic issues. High-profile examples of recent deals include Qiagen’s (Hilden, Germany) acquisition of TianWei Times (Beijing) and PG Biotech (Shenzhen); GNI’s (Tokyo, Japan) merger with Shanghai Genomics (Shanghai); and Invitrogen’s (Carlsbad, California) purchase of Shanghai BioAsia Biotechnology (Shanghai).

As biotechnology and pharmaceutical firms are increasingly looking to M&As as a viable strategy for growth, diversification and risk management, the "right" Chinese firms can be expected to garner much attention from Western suitors.

Three recent developments in Chinese law may influence a firm’s decision to enter China.

Regulation on Foreign Investment

As part of its rapidly developing regulatory regime, China recently amended its rules governing the acquisition of domestic companies by foreign investors. The new rules represent a further acceptance of cross-border M&As in line with international practice in that they expressly permit the use of equity consideration in corporate transactions, which was not feasible in the past. This development should be welcomed by research-based or clinical-stage firms that often rely on equity consideration as a primary currency in financing transactions.

Unfortunately, the regulators’ attempt to move quickly to establish a robust regulatory framework has left some ambiguities that may cause concern. For example, the new rules provide an additional layer of scrutiny by the ministry of commerce if the merger "involves any critical industry, affects or may affect the security of [the] national economy, or causes transference of actual control over the domestic enterprise who possesses a resound trademark or China’s time-honored brand." However, the terms "critical industry", "affects", "security of the national economy", "resound trademark", and "time-honored brand" are all undefined and appear to give considerable discretion to regulators to reject or unwind transactions. Commentators have opined that this uncertainty, coupled with existing limits on foreign investment in industries such as energy, communications, media, auto manufacturing and finance, may have a negative impact on the overall level of M&A activity.

Even so, the cost-benefit analysis favours firms’ transacting in the biotechnology industry since foreign investment and participation has, by and large, been encouraged by the Chinese government in the past. There is little indication that this trend would not continue in the future or that the new rules would be used to hinder transactions in this industry.

The key to M&As in China is patience. A deal can take several months longer to close in China than elsewhere because more regulatory approvals are typically needed. Furthermore, foreign firms need to be flexible in dealing with potential targets because the latter would likely be relatively small and unfamiliar with the M&A process. As with all M&A transactions, doing the right homework and taking the right due diligence approach will go a long way to alleviating future difficulties.

Corporate Tax Reform

A longer-term consideration for foreign firms is the Chinese government’s planned unification of corporate tax rates. Reports suggest that lawmakers plan to enact a bill that would eventually unify income tax rates for domestic and foreign companies at 25 per cent. Currently, the rates stand at 15 per cent for foreign companies and 33 per cent for their domestic peers. Even though this reform has resulted in a more costly operating environment, the planned unified rate is still relatively low compared with rates in developed markets.

However, what is more important for biotechnology firms is the accompanying reform to China’s preferential tax policies, which have in the past focused on geographical locations such as designated Hi-Tech Industry Development Zones and Special Economic Zones. The new policies will instead focus on designated industries. Reports suggest that "encouraged" hi-tech enterprises will be eligible for a reduced income tax rate of 15 per cent, and more tax incentives will be granted to start-up companies.

Though the text of the new corporate tax bill and accompanying policies have not yet been released, indications are that the government’s historical support of the biotechnology industry will be retained or strengthened through tax incentives.

Strengthened IP Protection

Any discussion about biotechnology in China must include the issue of IP protection. Indications are that China may have finally turned the corner on this front, as exemplified by the now-famous Viagra (sildenafil citrate) saga. After overturning the Patent Review Board’s decision invalidating Pfizer’s Chinese patents in June 2006, the Beijing No. 1 Intermediate People’s Court again upheld the validity of the patents in December 2006, in an infringement action against two Chinese generic manufacturers.

The very fact that generic companies have gone to court to challenge Pfizer’s patents, instead of simply marketing infringing products, is itself evidence of the maturation of the Chinese IP regime. This, coupled with similar court victories for the likes of Starbucks, Louis Vuitton and Prada in trademark cases, indicates a greater acceptance of the force of IP rights. This should provide some assurance for biotechnology firms looking to invest in China.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions